These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33247498)

  • 81. Development of Prostate Cancer Organoid Culture Models in Basic Medicine and Translational Research.
    Elbadawy M; Abugomaa A; Yamawaki H; Usui T; Sasaki K
    Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32218271
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Organotypic Models of Lung Cancer.
    Pomerenke A
    Curr Top Microbiol Immunol; 2021; 430():161-181. PubMed ID: 29423618
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Innovative multidimensional models in a high-throughput-format for different cell types of endocrine origin.
    Bornstein S; Shapiro I; Malyukov M; Züllig R; Luca E; Gelfgat E; Beuschlein F; Nölting S; Berruti A; Sigala S; Peitzsch M; Steenblock C; Ludwig B; Kugelmeier P; Hantel C
    Cell Death Dis; 2022 Jul; 13(7):648. PubMed ID: 35879289
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Cancer Explant Models.
    Stackhouse CT; Gillespie GY; Willey CD
    Curr Top Microbiol Immunol; 2021; 430():131-160. PubMed ID: 30888548
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Current status and perspectives of patient-derived rare cancer models.
    Kondo T
    Hum Cell; 2020 Oct; 33(4):919-929. PubMed ID: 32537685
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The secret lives of cancer cell lines.
    Hynds RE; Vladimirou E; Janes SM
    Dis Model Mech; 2018 Nov; 11(11):. PubMed ID: 30459183
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Patient-Derived Xenograft: A More Standard "Avatar" Model in Preclinical Studies of Gastric Cancer.
    Zeng M; Pi C; Li K; Sheng L; Zuo Y; Yuan J; Zou Y; Zhang X; Zhao W; Lee RJ; Wei Y; Zhao L
    Front Oncol; 2022; 12():898563. PubMed ID: 35664756
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Radiation Sensitivity: The Rise of Predictive Patient-Derived Cancer Models.
    Berube LL; Nickel KP; Iida M; Ramisetty S; Kulkarni P; Salgia R; Wheeler DL; Kimple RJ
    Semin Radiat Oncol; 2023 Jul; 33(3):279-286. PubMed ID: 37331782
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Failure to progress: breast and prostate cancer cell lines in developing targeted therapies.
    James C; Whitehead A; Plummer JT; Thompson R; Badal S
    Cancer Metastasis Rev; 2024 Jul; ():. PubMed ID: 39060878
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Characterizing and Exploiting Tumor Microenvironments to Optimize Treatment Outcomes.
    Allott EH; Dean K; Robson T; Meaney C
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830906
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Patient-Derived Cancer Models.
    Di Renzo MF; Corso S
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33333972
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Prostate cancer and therapeutic challenges.
    Hawsawi YM; Zailaie SA; Oyouni AAA; Alzahrani OR; Alamer OM; Aljohani SAS
    J Biol Res (Thessalon); 2020 Dec; 27(1):20. PubMed ID: 33303035
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Heterogeneous induction of an invasive phenotype in prostate cancer cells by coculturing with patient-derived fibroblasts.
    Ishii K; Nakagawa Y; Matsuda C; Katoh D; Ichishi M; Shirai T; Hirokawa Y; Fujiwara M; Sugimura Y; Watanabe M
    J Cell Biochem; 2021 Jun; 122(6):679-688. PubMed ID: 33480080
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Vitamin D sufficiency enhances differentiation of patient-derived prostate epithelial organoids.
    McCray T; Pacheco JV; Loitz CC; Garcia J; Baumann B; Schlicht MJ; Valyi-Nagy K; Abern MR; Nonn L
    iScience; 2021 Jan; 24(1):101974. PubMed ID: 33458620
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Clinical and Biological Features of Neuroendocrine Prostate Cancer.
    Yamada Y; Beltran H
    Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The use of zebrafish model in prostate cancer therapeutic development and discovery.
    Amawi H; Aljabali AAA; Boddu SHS; Amawi S; Obeid MA; Ashby CR; Tiwari AK
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):311-325. PubMed ID: 33392639
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Prostate cancer patient-derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens.
    Servant R; Garioni M; Vlajnic T; Blind M; Pueschel H; Müller DC; Zellweger T; Templeton AJ; Garofoli A; Maletti S; Piscuoglio S; Rubin MA; Seifert H; Rentsch CA; Bubendorf L; Le Magnen C
    J Pathol; 2021 Aug; 254(5):543-555. PubMed ID: 33934365
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.
    Wong RL; Yu EY
    Curr Treat Options Oncol; 2021 Jan; 22(2):13. PubMed ID: 33433743
    [TBL] [Abstract][Full Text] [Related]  

  • 99. The anti-inflammatory properties of the methanolic extract of
    Rajasree RS; Ittiyavirah SP; Poonkuzhi Naseef P; Saheer Kuruniyan M; Elayadeth-Meethal M; Sankar S
    Saudi J Biol Sci; 2022 Sep; 29(9):103396. PubMed ID: 35942162
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
    Pamarthy S; Sabaawy HE
    Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.